

# Richard Musil

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2774403/publications.pdf>

Version: 2024-02-01

53  
papers

1,723  
citations

304368

22  
h-index

288905

40  
g-index

57  
all docs

57  
docs citations

57  
times ranked

2723  
citing authors

#	ARTICLE	IF	CITATIONS
1	Celecoxib treatment in an early stage of schizophrenia: Results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. <i>Schizophrenia Research</i> , 2010, 121, 118-124.	1.1	227
2	Weight gain and antipsychotics: a drug safety review. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 73-96.	1.0	155
3	Update on weight-gain caused by antipsychotics: a systematic review and meta-analysis. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 295-314.	1.0	122
4	Low-Grade Inflammation as a Predictor of Antidepressant and Anti-Inflammatory Therapy Response in MDD Patients: A Systematic Review of the Literature in Combination With an Analysis of Experimental Data Collected in the EU-MOODINFLAME Consortium. <i>Frontiers in Psychiatry</i> , 2019, 10, 458.	1.3	111
5	Review and Consensus on Pharmacogenomic Testing in Psychiatry. <i>Pharmacopsychiatry</i> , 2021, 54, 5-17.	1.7	96
6	Withdrawal Symptoms and Rebound Syndromes Associated with Switching and Discontinuing Atypical Antipsychotics: Theoretical Background and Practical Recommendations. <i>CNS Drugs</i> , 2013, 27, 545-572.	2.7	88
7	Outcomes of 1014 naturalistically treated inpatients with major depressive episode. <i>European Neuropsychopharmacology</i> , 2010, 20, 346-355.	0.3	72
8	Homer-1 polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. <i>Journal of Psychiatric Research</i> , 2011, 45, 234-241.	1.5	55
9	The vicious circle of social exclusion and psychopathology: a systematic review of experimental ostracism research in psychiatric disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 521-532.	1.8	51
10	Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2005, 255, 432-437.	1.8	49
11	Monocyte mitochondrial dysfunction, inflammaging, and inflammatory pyroptosis in major depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 111, 110391.	2.5	43
12	Efficacy of olanzapine versus quetiapine on cognitive dysfunctions in patients with an acute episode of schizophrenia. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2007, 257, 402-412.	1.8	40
13	A genetic variant of HTR2C may play a role in the manifestation of Tourette syndrome. <i>Psychiatric Genetics</i> , 2010, 20, 35-38.	0.6	39
14	SNAP-25 gene polymorphisms and weight gain in schizophrenic patients. <i>Journal of Psychiatric Research</i> , 2008, 42, 963-970.	1.5	38
15	Three-Year long-term outcome of 458 naturalistically treated inpatients with major depressive episode: severe relapse rates and risk factors. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2014, 264, 567-575.	1.8	38
16	One-year functional outcomes of naturalistically treated patients with schizophrenia. <i>Psychiatry Research</i> , 2012, 198, 378-385.	1.7	34
17	Subtypes of depression and their overlap in a naturalistic inpatient sample of major depressive disorder. <i>International Journal of Methods in Psychiatric Research</i> , 2018, 27, .	1.1	34
18	High Kynurenine (a Tryptophan Metabolite) Predicts Remission in Patients with Major Depression to Add-on Treatment with Celecoxib. <i>Frontiers in Psychiatry</i> , 2017, 8, 16.	1.3	33

#	ARTICLE	IF	CITATIONS
19	Associations of SNAP-25 polymorphisms with cognitive dysfunctions in Caucasian patients with schizophrenia during a brief trial of treatment with atypical antipsychotics. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008, 258, 335-344.	1.8	32
20	Akathisia and Suicidal Ideation in First-Episode Schizophrenia. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 694-698.	0.7	29
21	Functional Outcomes in Schizophrenia: Employment Status as a Metric of Treatment Outcome. <i>Current Psychiatry Reports</i> , 2012, 14, 229-236.	2.1	27
22	Response trajectories in "real-world" naturalistically treated schizophrenia patients. <i>Schizophrenia Research</i> , 2012, 139, 218-224.	1.1	26
23	What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2015, 265, 107-116.	1.8	26
24	QTc prolongation in short-term treatment of schizophrenia patients: effects of different antipsychotics and genetic factors. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 383-390.	1.8	22
25	Genetics of emergent suicidality during antidepressive treatment" Data from a naturalistic study on a large sample of inpatients with a major depressive episode. <i>European Neuropsychopharmacology</i> , 2013, 23, 663-674.	0.3	21
26	Cathodal tDCS Over Motor Cortex Does Not Improve Tourette Syndrome: Lessons Learned From a Case Series. <i>Frontiers in Behavioral Neuroscience</i> , 2018, 12, 194.	1.0	20
27	Promotion of Wellbeing for Children of Parents With Mental Illness: A Model Protocol for Research and Intervention. <i>Frontiers in Psychiatry</i> , 2019, 10, 606.	1.3	20
28	Prevalence of obesity, metabolic syndrome, diabetes and risk of cardiovascular disease in a psychiatric inpatient sample: results of the Metabolism in Psychiatry (MiP) Study. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 597-609.	1.8	20
29	No influence of brain-derived neurotrophic factor (BDNF) polymorphisms on treatment response in a naturalistic sample of patients with major depression. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 405-412.	1.8	18
30	Positive clinical effects of gamma knife capsulotomy in a patient with deep brain stimulation-refractory Tourette Syndrome and Obsessive Compulsive Disorder. <i>Clinical Neurology and Neurosurgery</i> , 2018, 170, 34-37.	0.6	15
31	Associations of NEUROD2 polymorphisms and change of cognitive dysfunctions in schizophrenia and schizoaffective disorder after eight weeks of antipsychotic treatment. <i>Cognitive Neuropsychiatry</i> , 2017, 22, 280-297.	0.7	14
32	Is the efficacy of psychopharmacological drugs comparable to the efficacy of general medicine medication?. <i>BMC Medicine</i> , 2012, 10, 17.	2.3	13
33	The CNR1 gene in depression and schizophrenia " Is there an association with early improvement and response?. <i>Psychiatry Research</i> , 2012, 196, 160.	1.7	11
34	Pleckstrin homology domain containing 6 protein (PLEKHA6) polymorphisms are associated with psychopathology and response to treatment in schizophrenic patients. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2014, 51, 190-195.	2.5	10
35	Efficacy of Sertraline Plus Placebo or Add-On Celecoxib in Major Depressive Disorder: Macrophage Migration Inhibitory Factor as a Promising Biomarker for Remission After Sertraline" Results From a Randomized Controlled Clinical Trial. <i>Frontiers in Psychiatry</i> , 2021, 12, 615261.	1.3	10
36	Validity of remission and recovery criteria for schizophrenia and major depression: comparison of the results of two one-year follow-up naturalistic studies. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 303-313.	1.8	8

#	ARTICLE	IF	CITATIONS
37	What happens with schizophrenia patients after their discharge from hospital? Results on outcome and treatment from a "real-world" 2-year follow-up trial. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 661-671.	1.8	7
38	Sequential Social Exclusion in a Novel Cyberball Paradigm Leads to Reduced Behavioral Repair and Plasma Oxytocin in Borderline Personality Disorder. <i>Journal of Personality Disorders</i> , 2022, 36, 99-115.	0.8	6
39	Chronic vs non-chronic depression in psychiatric inpatient care - Data from a large naturalistic multicenter trial. <i>Journal of Affective Disorders</i> , 2022, 299, 73-84.	2.0	6
40	Challenging the understanding of significant improvement and outcome in schizophrenia " the concept of reliable and clinically significant change methods. <i>International Journal of Methods in Psychiatric Research</i> , 2016, 25, 3-11.	1.1	5
41	Remission in schizophrenia " What are we measuring? Comparing the consensus remission criteria to a CGI-based definition of remission and to remission in major depression. <i>Schizophrenia Research</i> , 2019, 209, 185-192.	1.1	5
42	Polygenic analysis suggests the involvement of calcium signaling in executive function in schizophrenia patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 270, 425-431.	1.8	5
43	Assessing the links between childhood trauma, C-reactive protein and response to antidepressant treatment in patients with affective disorders. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 1331-1341.	1.8	4
44	Lifestyle behaviors, metabolic disturbances, and weight gain in psychiatric inpatients treated with weight gain-associated medication. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 0, , .	1.8	4
45	Add-on Antidepressants in the Naturalistic Treatment of Schizophrenia Spectrum Disorder " When, Who, and How?. <i>Pharmacopsychiatry</i> , 2017, 50, 136-144.	1.7	3
46	Altered immediate behavioral response to partial social exclusion: A cross-diagnostic study in patients with borderline personality disorder and persistent depressive disorder. <i>Journal of Psychiatric Research</i> , 2021, 144, 177-183.	1.5	3
47	Safety evaluation of zotepine for the treatment of schizophrenia. <i>Expert Opinion on Drug Safety</i> , 2010, 9, 659-666.	1.0	2
48	Pharmacogenetics and cognitive symptoms in schizophrenia patients treated with antipsychotics. <i>Pharmacogenomics</i> , 2018, 19, 927-930.	0.6	2
49	Effectiveness of Quetiapine in Outpatients With Schizophrenia Assessed Under "Real-Life" Conditions. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 120-122.	0.7	1
50	SU105BRAIN CELL TYPE-SPECIFIC POLYGENIC RISK IN SCHIZOPHRENIA: INFLUENCE ON CLINICAL PHENOTYPES. <i>European Neuropsychopharmacology</i> , 2019, 29, S1322.	0.3	0
51	Comparing Schizophrenia Patients With a Predicted High/Low Risk of Nonresponse Receiving Treatment with Ziprasidone and Haloperidol: A Randomized-Controlled Study. <i>Pharmacopsychiatry</i> , 2019, 52, 180-185.	1.7	0
52	Early Improvement and Its Predictive Validity in First-Episode Schizophrenia Patients. , 2011, , 93-107.		0
53	Suicidality and Outcome in Schizophrenia Patients. , 2011, , 365-382.		0